LRFN2 is also associated with obesity-related traits (Comuzzie et al., 2012), cognitive performance (Lee et al., 2018), EA (Okbay et al., 2022), psychiatric conditions such as insomnia (Watanabe et al., 2022) and schizophrenia (Trubetskoy et al., 2022), and multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma) (Jin et al., 2012). Here, LRFN2 is linked to obesity due to melanocortin 4 receptor deficiency.